Novo Not Discussing Further Pill Discounts, CEO Says
Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the hype. "We are not right now discussing further discounts," Doustdar tells Bloomberg's Francine Lacqua. (Source: Bloomberg)
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
